BLTE News

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

Belite Bio to Participate in Four Upcoming Investor Conferences

Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease